Malignancies and soluble tumor antigens in rheumatic diseases

Autoimmunity Reviews

Volumn 6, Issue 1, 2006, Pages 42-47

  Szekanecz, Éva ^a   András, Csilla ^a   Sándor, Zsuzsa ^a   Antal Szalmás, Péter ^a   Szántó, János ^a   Tamási, László ^b   Kiss, Emese ^a   Szekanecz, Zoltán ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b Saint Francis Hospital   (Hungary)

Author keywords

Paraneoplasia; Rheumatic syndromes; Tumor associated antigens

Indexed keywords

ANTIBODY; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; HORMONE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PEPTIDE; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIGEN EXPRESSION; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CYTOTOXIC LYMPHOCYTE; DERMATOMYOSITIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG INDUCED CANCER; DRUG SAFETY; EARLY DIAGNOSIS; ESOPHAGUS CANCER; HUMAN; IMMUNE DEFICIENCY; INFLAMMATION; INFLAMMATORY CELL; LUNG CANCER; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDIATOR; METASTASIS; MUTAGENESIS; OSTEOSARCOMA; OVARY CANCER; PAGET BONE DISEASE; PARACRINE SIGNALING; PARANEOPLASTIC SYNDROME; POSTMARKETING SURVEILLANCE; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK FACTOR; SCLERODERMA; SJOEGREN SYNDROME; SKIN CANCER; SMOKING; SOLID TUMOR; STOMACH CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

ANTIGENS, NEOPLASM; AUTOIMMUNE DISEASES; HUMANS; PARANEOPLASTIC SYNDROMES; RHEUMATIC DISEASES;

EID: 33750829948     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2006.03.007     Document Type: Review

References (36)

1. Chakravarty E., and Genovese M.C. Rheumatic syndromes associated with malignancy. Curr Opin Rheumatol 15 (2003) 35-43
2. Nashitz J.E. Rheumatic syndromes: clues to occult neoplasia. Curr Opin Rheumatol 13 (2001) 62-66
3. Marmur R., and Kagen L. Cancer-associated neuromusculoskeletal syndromes. Postgrad Med 111 (2002) 4
4. Schwarzer A.C., and Schrieber L. Rheumatic manifestations of neoplasia. Curr Opin Rheumatol 3 (1991) 145-154
5. Stertz G. Polymyositis. Berl Klin Wochenshr 53 (1916) 489
6. Callen J.P. Relationship of cancer to inflammatory muscle disease. Dermatomyositis, polymyositis and inclusion body myositis. Rheum Dis Clin North Am 20 (1994) 943-953
7. Rider L.G., and Miller F.W. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 23 (1997) 619-655
8. Whitmore S.E., Watson R., Rosenshein N.B., and Provost T.T. Dermatomyositis sine myositis: association with malignancy. J Rheumatol 23 (1996) 101-105
9. Airio A., Pukkala E., and Isomaki H. Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22 (1995) 1300-1303
10. Freundlich B., Makover D., and Maul G.G. A novel antinuclear antibody associated with a lupus-like paraneoplastic syndrome. Ann Intern Med 109 (1988) 295-297
11. Leandro M.J., and Alsenberg D. Rheumatic diseases and malignancy-is there an association?. Scand J Rheumatol 30 (2001) 185-188
12. Hamidou M.A., Derenne S., Audrain M.A.P., Berthelot J.M., Boumalassa A., and Grolleau J.Y. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. Rheumatology 39 (2000) 417-420
13. Shih W.-J. Pulmonary hypertrophic osteoarthropathy and its resolution. Semin Nucl Med 34 (2004) 159-163
14. Hall R., Hopkinson N., and Hamblin T. Relapsing polychondritis, smouldering non-secretory myeloma and early myelodysplastic syndrome in the same patient: three difficult diagnoses produce a life threatening illness. Leuk Res 24 (2000) 91-93
15. Enomoto M., Takemura H., Suzuki M., Yuhara T., Akama T., Yamane K., et al. Palmar fasciitis and polyarthritis associated with gastric carcinoma: complete resolution after total gastrectomy. Int Med 39 (2000) 9
16. Preiss J.C., Faiss S., Loddenkemper C., Zeitz M., and Duchmann R. Pancreatic panniculitis in an 88-year-old man with neuroendocrine carcinoma. Digestion 66 (2002) 193-196
17. Kassan S.S., Thomas T.L., Moutsopoulos H., Hoover R., Kimberly R.P., Budman D.R., et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89 (1978) 888-892
18. Pijpe J., van Imhoff G.W., Spijkervet F.K., Roodenburg J.L., Wolbink G.J., Mansour K., et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum 52 (2005) 2740-2750
19. Gridley G., McLaughlin J.K., Ekbom A., Klareskog L., Adami H.O., Hacker D.G., et al. Incidence of cancer among patients with rheumatoid arthritis. J Natl Cancer Inst 85 (1993) 307-311
20. Mellemkjaer L., Linet M.S., Gridley G., Frisch M., Moller H., and Olsen J.H. Rheumatoid arthritis and cancer risk. Eur J Cancer 32A (1996) 1753-1757
21. Pettersson T., Pukkala E., Teppo L., and Friman C. Increased risk of cancer in patients with systemic lupus erythematosus. Ann Rheum Dis 51 (1992) 437-439
22. Lopez Dupla M., Khamashta M., Pintado Garcia V., Lavilla Uriol P., Valencia Ortega E., and Gil Aguado A. Malignancy in systemic lupus erythematosus. Lupus 2 (1993) 377-380
23. Abu-Shakra M., Guillemin F., and Lee P. Cancer in systemic sclerosis. Arthritis Rheum 36 (1993) 460-467
24. Asten P., Barrett J., and Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 26 (1999) 1705-1711
25. Kinlen L.J. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 21 (1985) 44-49
26. Beauparlent P., Papp K., and Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29 (1999) 148-154
27. Brown S.L., Greene M.H., Gershon S.K., Edwards E.T., and Brown M.M. Tumor necrosis factor antagonist therapy and lymphoma development. Arthritis Rheum 46 (2002) 3151-3158
28. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
29. Szekanecz Z., Haines G.K., Harlow L.A., Shah M.R., Fong T.W., Fu R., et al. Increased synovial expression of the adhesion molecules CD66a, CD66b and CD31 in rheumatoid and osteoarthritis. Clin Immunol Immunopathol 76 (1995) 180-186
30. Torsteinsdottir I., Arvidson N.G., Hallgren R., and Hakansson L. Enhanced expression of integrins and CD66b on peripheral blood neutrophils and eosinophils in patients with rheumatoid arthritis and the effect of glucocorticoids. Scand J Immunol 50 (1999) 433-439
31. Unger A., Panayi G.S., and Lessof M.H. Carcinoembryonic antigen in rheumatic diseases. Rheumatol Rehabil 14 (1975) 19-24
32. Shimomura C., Eguchi K., Kawakami A., Migita K., Nakao H., Otsubo Y., et al. Elevation of tumor associated antigen CA19-9 levels in patients with rheumatic diseases. J Rheumatol 16 (1989) 1410-1415
33. Kimura K., Ezoe K., Yokozeki H., Katayama I., and Nishioka K. Elevated serum CA125 in progressive systemic sclerosis with pleural effusion. J Dermatol 22 (1995) 28-31
34. Valerio-Marzano A., Morabito A., Berti E., and Caputo R. Elevated circulating CA15.3 levels in a subset of systemic sclerosis with severe lung involvement. Arch Dermatol 134 (1998) 645
35. Takeda N., Ihn H., and Teramoto S. Markedly increased levels of IL-6 and CA125 in pleural fluids of an elderly person with overlap syndrome of systemic sclerosis and systemic lupus erythematosus. Age Ageing 30 (2001) 171
36. Safadi R., Ligumsky M., Goldin E., Ilan Y., Haviv Y.S., and Nusair S. Increased serum CA19-9 antibodies in Sjögren's syndrome. Postgrad Med J 74 (1998) 543-544